Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pseudomonas aeruginosa immunotherapy.

× No keyword cloud information.

36 in total

1. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody.

Authors: R F Hector; M S Collins; J E Pennington
Journal: J Infect Dis Date: 1989-09 Impact factor: 5.226

2. Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.

Authors: H Y Reynolds; J A Kazmierowski; H H Newball
Journal: J Clin Invest Date: 1975-08 Impact factor: 14.808

3. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations.

Authors: I A Holder; J G Naglich
Journal: J Trauma Date: 1986-02

4. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors: H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal: Infect Immun Date: 1988-08 Impact factor: 3.441

5. A new polyvalent Pseudomonas vaccine.

Authors: J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal: J Med Microbiol Date: 1977-02 Impact factor: 2.472

6. Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors: P Ames; D DesJardins; G B Pier
Journal: Infect Immun Date: 1985-08 Impact factor: 3.441

7. The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa.

Authors: L S Young; R P Wenzel; L D Sabath; M Pollack; J E Pennington; R Platt
Journal: Rev Infect Dis Date: 1984 Sep-Oct

8. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors: G B Pier; W J Matthews; D D Eardley
Journal: J Infect Dis Date: 1983-03 Impact factor: 5.226

9. Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa.

Authors: S Sawada; T Kawamura; Y Masuho
Journal: J Gen Microbiol Date: 1987-12

10. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.

Authors: O R Pavlovskis; D C Edman; S H Leppla; B Wretlind; L R Lewis; K E Martin
Journal: Infect Immun Date: 1981-05 Impact factor: 3.609

6 in total

Review 1. Immunological perspectives in prevention and treatment of nosocomial pneumonia.

Authors: J E Pennington
Journal: Intensive Care Med Date: 1992 Impact factor: 17.440

2. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.

Authors: M J Preston; A A Gerçeker; M E Reff; G B Pier
Journal: Infect Immun Date: 1998-09 Impact factor: 3.441

3. Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response.

Authors: J W Murphy
Journal: Infect Immun Date: 1993-11 Impact factor: 3.441

4. Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans.

Authors: J W Murphy; M R Hidore; S C Wong
Journal: J Clin Invest Date: 1993-04 Impact factor: 14.808

5. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors: G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal: Infect Immun Date: 1994-04 Impact factor: 3.441

6. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors: K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal: Infect Immun Date: 1994-09 Impact factor: 3.441

6 in total